[go: up one dir, main page]

MX2018004580A - Metodo para producir proteina de fusion con dominio fc de igg. - Google Patents

Metodo para producir proteina de fusion con dominio fc de igg.

Info

Publication number
MX2018004580A
MX2018004580A MX2018004580A MX2018004580A MX2018004580A MX 2018004580 A MX2018004580 A MX 2018004580A MX 2018004580 A MX2018004580 A MX 2018004580A MX 2018004580 A MX2018004580 A MX 2018004580A MX 2018004580 A MX2018004580 A MX 2018004580A
Authority
MX
Mexico
Prior art keywords
fusion protein
igg
domain
producing fusion
preparing
Prior art date
Application number
MX2018004580A
Other languages
English (en)
Inventor
Jae Park Soon
Shin Chung Hye
Ah You Sun
Soo Cho Jeong
Original Assignee
Alteogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58703642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018004580(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alteogen Inc filed Critical Alteogen Inc
Priority claimed from PCT/KR2016/011561 external-priority patent/WO2017065559A1/ko
Publication of MX2018004580A publication Critical patent/MX2018004580A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

La presente invención se refiere a un método para preparar una proteína de fusión con un dominio Fc de lgG y, específicamente, a un método para preparar una proteína de fusión con un dominio Fc de lgG, comprendiendo adicionalmente el método una etapa de cultivo de células, que producen la proteína de fusión., a una temperatura de cultivo disminuida, aumentando así el crecimiento celular y la viabilidad celular a fin de aumentar la productividad de la proteína de fusión e inhibir la generación de agregados para de esta forma mejorar la calidad y el rendimiento de la producción.
MX2018004580A 2015-10-15 2016-10-14 Metodo para producir proteina de fusion con dominio fc de igg. MX2018004580A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20150144330 2015-10-15
KR1020160132633A KR101936049B1 (ko) 2015-10-15 2016-10-13 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
PCT/KR2016/011561 WO2017065559A1 (ko) 2015-10-15 2016-10-14 Igg fc 도메인을 가지는 융합 단백질의 생산방법

Publications (1)

Publication Number Publication Date
MX2018004580A true MX2018004580A (es) 2018-09-19

Family

ID=58703642

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004580A MX2018004580A (es) 2015-10-15 2016-10-14 Metodo para producir proteina de fusion con dominio fc de igg.

Country Status (11)

Country Link
US (2) US11414476B2 (es)
EP (2) EP4098659A1 (es)
JP (2) JP6783305B2 (es)
KR (1) KR101936049B1 (es)
CN (2) CN108137672B (es)
AU (1) AU2016339642B2 (es)
CA (1) CA3001977C (es)
ES (1) ES2945537T3 (es)
MX (1) MX2018004580A (es)
PL (1) PL3363811T3 (es)
RU (1) RU2732237C2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2018194413A1 (en) 2017-04-21 2018-10-25 Yuhan Corporation Method for producing dual function proteins and its derivatives
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN115197961B (zh) * 2022-06-20 2024-04-16 岭南现代农业科学与技术广东省实验室肇庆分中心 一种非洲猪瘟病毒b602l重组蛋白稳定表达细胞系及其构建方法和应用
JP2025541413A (ja) * 2022-12-27 2025-12-18 ネクスセラ カンパニー リミテッド エラスチン類似ポリペプチド基盤の組換えタンパク質の作製及びその動物細胞発現プラットフォーム
CN119613573B (zh) * 2025-02-14 2025-05-30 浙江大学 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
ATE417928T1 (de) * 1999-06-08 2009-01-15 Regeneron Pharma Vegf-rezeptorchimären zur behandlung von augenkrankheiten, welche durch vaskuläre permeabilität charakterisiert sind.
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
WO2003020906A2 (en) * 2001-08-31 2003-03-13 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
AU2003300276B2 (en) * 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
EP2432476A4 (en) 2009-05-01 2013-03-20 Ophthotech Corp METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
LT3330370T (lt) * 2010-04-26 2021-06-10 Novartis Ag Cho ląstelių auginimo būdas
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
KR20150038297A (ko) 2012-08-02 2015-04-08 사노피 아플리베르셉트 또는 지브-아플리베르셉트를 포함하는 제조 물품
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
MX362922B (es) 2013-03-26 2019-02-25 Coherus Biosciences Inc Método de producción de proteínas.
CN105122729B (zh) 2013-04-15 2020-01-07 瑞典爱立信有限公司 去往mtc设备的系统信息的信令发送
WO2015000181A1 (zh) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
CN103319610B (zh) 2013-07-05 2016-01-27 华博生物医药技术（上海）有限公司 重组融合蛋白及其制法和用途
WO2015116315A1 (en) 2014-01-29 2015-08-06 Amgen Inc. Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
CN104974262B (zh) * 2014-04-04 2019-08-09 华博生物医药技术（上海）有限公司 重组双功能融合蛋白及其制法和用途
CN106536746A (zh) * 2014-06-03 2017-03-22 鲁宾有限公司 用于生产蛋白的细胞培养方法
KR20160132633A (ko) 2015-05-11 2016-11-21 주식회사 엘지화학 배터리 시스템 및 그 연결 제어 방법
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
TW202140776A (zh) 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基

Also Published As

Publication number Publication date
KR20170044594A (ko) 2017-04-25
CN115247196A (zh) 2022-10-28
RU2018117705A3 (es) 2019-11-15
JP2020114266A (ja) 2020-07-30
KR101936049B1 (ko) 2019-01-08
PL3363811T3 (pl) 2023-07-17
CA3001977A1 (en) 2017-04-20
JP6783305B2 (ja) 2020-11-11
BR112018007590A2 (pt) 2018-10-23
US20220348636A1 (en) 2022-11-03
US11414476B2 (en) 2022-08-16
JP2018530344A (ja) 2018-10-18
EP3363811B1 (en) 2023-04-19
RU2018117705A (ru) 2019-11-15
US20180298078A1 (en) 2018-10-18
CN108137672A (zh) 2018-06-08
EP3363811A1 (en) 2018-08-22
EP3363811A4 (en) 2019-03-13
EP4098659A1 (en) 2022-12-07
RU2732237C2 (ru) 2020-09-14
AU2016339642A1 (en) 2018-04-12
ES2945537T3 (es) 2023-07-04
CA3001977C (en) 2023-06-20
AU2016339642B2 (en) 2019-07-25
CN108137672B (zh) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
CY1123146T1 (el) Καλλιεργεια κυτταρου θηλαστικου
EP4446338A3 (en) Cells and method of cell culture
WO2011134919A3 (en) Cho cells cultivation process 0
NZ630568A (en) Methods and means for the production of ch3 domain-comprising molecules
MY203897A (en) Methods of producing omega-hydroxylated fatty acid derivatives
MX2016012419A (es) Formas solidas de ibrutinib y procesos para la produccion de las mismas.
WO2012171030A3 (en) Method and apparatus for antibody production and purification
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
BR112017021255A2 (pt) microrganismo modificado para a produção otimizada de 2,4-di-hidroxibutirato
MX2018002705A (es) Cepas de levadura para la expresion y secrecion de proteinas heterologas a altas temperaturas.
WO2016171224A9 (ja) タンパク質の分泌生産法
MX2016010236A (es) Modulacion del crecimiento celular y glucosilacion en la produccion de glucoproteina recombinante.
EP3597664A3 (en) Temperature shift for high yield expression of polypeptides in yeast and other transformed cells
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
EP2762003A4 (en) AGROCHEMICAL COMPOSITION, ITS USE AND METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR PROVIDING HIGH PLANT PRODUCTIVITY
PH12016502406A1 (en) Cell culture process for producing a protein
PH12019501001A1 (en) Method for preparing electrocompetent yeast cells, and method for using said cells
EP3778880A4 (en) Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells
NZ749715A (en) Leuconostoc mesenteroides cjlm119 strain producing reduced amount of gas, and kimchi production method using same
MX2022003016A (es) Metodo de produccion con iones de cobre controlados.
MX2021001981A (es) Metodos para preparar un poloxamero para usar en medio de cultivo celular.
EA201301294A1 (ru) Получение высокочистых мультисубъединичных белков, таких как антитела, в трансформированных микроорганизмах, например pichia pastoris
SG10201808061WA (en) Method for the clarification of high density crude cell culture harvest
WO2011085095A3 (en) Enhanced protein expression